Serrati C, Marchal G, Rioux P, Viader F, Petit-Taboué M C, Lochon P, Luet D, Derlon J M, Baron J C
Centre Cyceron, Caen, France.
J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):174-9. doi: 10.1136/jnnp.57.2.174.
Contralateral cerebellar hypometabolism (CCH) is a well established remote functional effect of cerebral damage. Because CCH has been reported to be reversible in acute stroke in at least some patients, the value of cerebellar metabolic asymmetry (CbMA; a reflection of the degree of CCH) as a predictor of stroke outcome has been assessed. Measurements of cerebellar oxygen consumption were performed by positron emission tomography (PET) in 16 patients within 5-30 hours of onset of their first ever middle cerebral artery territory stroke, and again 13-56 days later in 12 survivors. The neurological state was quantified at the time of each PET study and at day 60, with both the Mathew and Orgogozo scales. In the early PET study, the CbMAs ranged from around 0% to nearly 50% (individually significant at p < 0.05 in 9/16 patients) but were neither strongly nor consistently correlated with neurological outcome or recovery at day 60. Similarly, the changes in CbMAs from the early to the late PET study were not correlated with the concomitant neurological evolution. At the late PET study, however, there were excellent positive correlations between CbMAs and both neurological status and size of infarction (assessed by CT in the chronic stage). The correlation with neurological status was explained by the correlation with size of infarction. The poor predictive value of CbMAs in the early PET study may be partly because the cerebral metabolic disturbance might still be evolving at this early stage in some cases. Despite this lack of a strong quantitative link between CbMAs at the early PET study and outcome, the outcome was good in all the patients who did not exhibit significant CCH, suggesting that lack of CCH may predict good outcome in acute middle cerebral artery stroke.
对侧小脑代谢减退(CCH)是一种已被充分证实的脑损伤远隔功能效应。由于据报道至少在部分急性卒中患者中CCH是可逆的,因此已经评估了小脑代谢不对称性(CbMA;CCH程度的一种反映)作为卒中预后预测指标的价值。对16例首次发生大脑中动脉供血区卒中且发病时间在5 - 30小时内的患者,通过正电子发射断层扫描(PET)测量小脑氧消耗,并在13 - 56天后对12例幸存者再次进行测量。在每次PET研究时以及第60天时,使用马修量表和奥戈戈佐量表对神经状态进行量化。在早期PET研究中,CbMA范围从约0%至近50%(在9/16例患者中个体差异显著,p < 0.05),但与第60天时的神经预后或恢复情况既无强相关性也无一致性关联。同样,从早期到晚期PET研究中CbMA的变化与伴随的神经进展情况也无相关性。然而,在晚期PET研究中,CbMA与神经状态以及梗死灶大小(在慢性期通过CT评估)之间存在极好的正相关性。与神经状态的相关性可通过与梗死灶大小的相关性来解释。早期PET研究中CbMA预测价值不佳可能部分是因为在某些情况下,此时脑代谢紊乱可能仍在演变。尽管早期PET研究中CbMA与预后之间缺乏强定量关联,但所有未表现出显著CCH的患者预后良好,这表明无CCH可能预示急性大脑中动脉卒中预后良好。